ORAL THERAPEUTICS AND PHARMACOLOGY
Online ISSN : 1884-4928
Print ISSN : 0288-1012
ISSN-L : 0288-1012
Investigation of medical insurance approval of dental medications at 10 national university dental hospitals in Japan
OSAMU FUJISHITAIKUO WADAAKIRA SUZUKISHINTARO KIMURAKATSUHISA ASAMIKATSUSHI FURUNOMICHIO KUMAGAIKAZUHIKO TERAOKAHIRONOBU KARASAWATETSUO MATSUMOTO
Author information
JOURNAL FREE ACCESS

2000 Volume 19 Issue 3 Pages 146-149

Details
Abstract
Medical insurance approval of dental medications at 10 national university dental hospitals in Japan was investigated. Some analgesic and antipyretic drugs, antibiotics, and anticancer agents were not covered by insurance for dental use in Japan. Examples of drugs not covered by insurance include Pontal® syrup (Mefenamic acid), Anhiba® suppository (Acetaminophen), Fosmicin-s® for injection (Fosfomycin sodium), Pentcillin for injection (Piperacillin sodium), Dalacin S® injection (Cli damycin phosphate), Minomycin®intravenous (Minocycline Hydrochloride), Oncovin®for injection (Vincristine sulfate), Nidran®for injection (Nimustine Hydrochloride), Krestin®, and Bestatine® capsule (Ubenimex) . These drugs are not indicated for dental use (off-label use), but expansion of medical insurance coverage for dental drugs is desired by Japanese dentists. To increase insurance coverage of medications, cooperation between medical administrative organs, medical and dental scientific societies, and pharmaceutical companies is necessary.
Content from these authors
© JAPANESE SOCIETY OF ORAL THERAPEUTICS AND PHARMACOLOGY
Previous article Next article
feedback
Top